IRIS
NUVOLONE, MARIO ULISSE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.459
EU - Europa 947
AS - Asia 638
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.048
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.454
CN - Cina 542
IE - Irlanda 504
FI - Finlandia 134
DE - Germania 103
SG - Singapore 70
IT - Italia 67
UA - Ucraina 50
SE - Svezia 18
BE - Belgio 13
FR - Francia 13
GB - Regno Unito 12
JP - Giappone 10
AT - Austria 9
IN - India 6
CA - Canada 5
ES - Italia 5
IR - Iran 4
LT - Lituania 4
NO - Norvegia 4
CH - Svizzera 3
HK - Hong Kong 2
KR - Corea 2
LU - Lussemburgo 2
MU - Mauritius 2
NL - Olanda 2
RU - Federazione Russa 2
AU - Australia 1
CZ - Repubblica Ceca 1
EU - Europa 1
MY - Malesia 1
RO - Romania 1
TR - Turchia 1
Totale 3.048
Salva come PNG Salva come JPEG
Città #
Dublin 504
Chandler 349
Nanjing 158
Ashburn 123
Boardman 99
Jacksonville 93
Helsinki 91
Princeton 73
Lawrence 68
Beijing 61
Wilmington 57
Singapore 54
Medford 53
Nanchang 53
Ann Arbor 52
Shanghai 45
Shenyang 40
Jiaxing 38
Hebei 35
Changsha 32
Pavia 30
Hangzhou 27
New York 20
Tianjin 20
Woodbridge 16
Norwalk 15
Redwood City 15
Brussels 13
Milan 11
Munich 11
Piscataway 11
Seattle 10
Tokyo 10
Dallas 9
Fairfield 9
Washington 9
Falkenstein 7
Los Angeles 6
Tamm 6
Chicago 5
Falls Church 4
Pune 4
Zhengzhou 4
Catania 3
L'Hospitalet de Llobregat 3
London 3
Ningbo 3
Toronto 3
Verona 3
Vienna 3
Bhubaneswar 2
Dongdaemun-gu 2
Hanover 2
Luxembourg 2
Nagold 2
Newark 2
Orange 2
Palermo 2
Redmond 2
Zurich 2
Altoona 1
Andover 1
Ardabil 1
Auburn Hills 1
Baltimore 1
Berlin 1
Borås 1
Brno 1
Cangzhou 1
Cervera del Rio Alhama 1
Changchun 1
Des Moines 1
Frankfurt am Main 1
Fuzhou 1
Guangzhou 1
Hefei 1
Houston 1
Jinan 1
Kemerovo 1
Kish 1
Kunming 1
Las Vegas 1
Lugano 1
Magenta 1
Markham 1
Miami 1
Nuremberg 1
Orlando 1
Paris 1
Richmond 1
Rockville 1
Sacramento 1
San Francisco 1
Santa Clara 1
Sassari 1
Selangor 1
Shiraz 1
Simi Valley 1
Sydney 1
Taiyuan 1
Totale 2.431
Salva come PNG Salva come JPEG
Nome #
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 84
Bone marrow amyloidosis. 83
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 79
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 77
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 69
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 69
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 67
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 62
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 60
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 59
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 56
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 55
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 55
Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney 52
Cystatin F is a biomarker of prion pathogenesis in mice 52
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 51
Prognostication of survival and progression to dialysis in AA amyloidosis 51
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis 50
Regulated expression of amyloidogenic immunoglobulin light chains in mice 49
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 49
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 47
Extended characterization of the novel co-isogenic C57BL/6J Prnp−/− mouse line 47
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 44
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 43
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 43
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 42
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 41
Altered monoaminergic systems and depressive-like behavior in congenic prion protein knock-out mice 41
The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease 40
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 40
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 40
Structure-based drug design identifies polythiophenes as antiprion compounds 39
Efficient amyloid A clearance in the absence of immunoglobulins and complement factors 39
The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6 38
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 37
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 37
The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis 35
Genome-wide transcriptomics identifies an early preclinical signature of prion infection 34
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 33
Cells and prions: A license to replicate 33
Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture 33
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses 33
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 32
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 31
Systemic amyloidosis: novel therapies and role of biomarkers 31
A neuroprotective role for microglia in prion diseases 31
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 31
Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling 30
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 30
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 30
Prion pathogenesis in the absence of NLRP3/ASC inflammasomes 29
Prion protein and Ab-related synaptic toxicity impairment 29
Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science 29
Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier 29
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 29
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 29
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 28
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 28
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy 27
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 27
The Priority position paper: Protecting Europe's food chain from prions 27
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 27
A case of monoclonal gammopathy of renal significance 27
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 26
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 26
The workings of the amyloid diseases. 25
The immunobiology of prion diseases 23
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 23
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 22
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 22
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis 22
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 22
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells 21
Redirecting proteoxicity 21
Management of the elderly patient with AL amyloidosis 19
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 18
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development 17
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression 16
Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice 16
New Insights Into a Multifaceted Disease 16
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 15
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis 15
Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions 14
Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability 13
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 12
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 10
Glial activation in prion diseases is selectively triggered by neuronal PrPSc 9
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 7
Transthyretin-associated familial amyloid polyneuropathy - current and emerging therapies 7
Renal amyloidoses 7
Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity 6
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 6
La medicina di laboratorio: Gli Specialisti di domani 6
null 6
Scaling analysis reveals the mechanism and rates of prion replication in vivo 5
The ASC inflammasome adapter governs SAA-derived protein aggregation in inflammatory amyloidosis 4
TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma 3
Prion diseases disrupt glutamate/glutamine metabolism in skeletal muscle 3
Development and Validation of Staging Systems for AA Amyloidosis 3
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 3
Totale 3.208
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020119 0 0 0 0 0 10 1 14 15 36 20 23
2020/2021165 15 9 6 15 7 17 11 42 8 17 16 2
2021/2022280 3 5 3 0 8 9 6 26 20 5 40 155
2022/20231.175 119 89 20 66 92 104 25 51 563 6 29 11
2023/2024471 59 103 25 28 46 102 16 26 6 18 22 20
2024/2025296 28 110 12 37 17 92 0 0 0 0 0 0
Totale 3.224